In August, a large number of pharmaceutical companies announced the suspension of production, suspension of business activities

"Pharmaceutical Network Industry Dynamics" Recently, Jiangxi Provincial Drug Administration issued a pharmaceutical company to stop production announcement.
announcement, Jiangxi Xiangyun Pharmaceutical Co., Ltd. for its own reasons, to the Jiangxi Provincial Bureau reported the discontinuation of Chinese medicine tablets.
statistics, since August, the bureau has announced nine pharmaceutical companies to stop production or suspend business activities.
five enterprises have voluntarily cancelled their "drug business licenses", two have applied for suspension of operations and two pharmaceutical production enterprises have stopped production.
According to incomplete statistics, since August, in addition to Jiangxi Province, Sichuan, Chongqing, Hainan, Fujian, Henan, Gansu, Liaoning, Heilongjiang, Yunnan, Jiangxi and other local drug regulatory bureaus have also issued a pharmaceutical company announced the suspension of production, suspension or closure of business activities.
August 27, the Sichuan Provincial Drug Administration issued a notice to cancel the "Drug Production License" of Chunyu Pharmaceutical Co., Ltd. of Sichuan Province.
August 25, the Chongqing Municipal Drug Administration issued a public announcement that it intends to cancel Chongqing Qiju Pharmaceutical Co., Ltd.'s "Drug Business License" because Chongqing Qiju Pharmaceutical Co., Ltd. ceased to operate drugs or closed down.
August 24, Hainan Provincial Drug Administration announced that Hainan Deli Pharmaceutical Technology Co., Ltd. and other seven pharmaceutical business enterprises " Drug Business License" expired, did not apply to the Bureau in accordance with the law for a new "Drug Business License" to cancel 7 enterprises "Drug Business License."
August 19, the Fujian Drug Administration issued a notice on the cancellation of Xiamen Reagent Biotech Co., Ltd. "Drug Production License."
the application of Xiamen Reagent Biotech Co., Ltd. and in accordance with the relevant provisions of the Measures for the Supervision and Administration of Drug Production, the Fujian Drug Administration cancelled the "Drug Production License" of the enterprise.
August 14, the Henan Provincial Drug Administration said it had received a report from Zhengzhou Antu Bioengineering Co., Ltd.
the enterprise, for its own reasons, reported to the provincial bureau that the production of pharmaceutical products had ceased.
August 12, Gansu Fuge Tibetan Pharmaceutical Co., Ltd. also because of the enterprise's own reasons, the initiative to Gansu Provincial Drug Administration to apply for discontinuation.
it is understood that since August 8, the company's pills (water honey pills, water pills), hard capsules, tablets, pretreated, extraction and other comprehensive stop production.
same day, the Liaoning Provincial Drug Administration issued a notice that Dalian Junda Pharmaceutical Co., Ltd. and six other pharmaceutical companies because of the termination of drug business, applied for the cancellation of the "drug business license", its "drug business license" was cancelled in accordance with the law.
August 11, Heilongjiang Provincial Drug Administration issued a notice that Harbin Yuheng Ambo Pharmaceutical Co., Ltd., Harbin Yuheng Yiwei Pharmaceutical Development Co., Ltd. two enterprises are currently closed, and take the initiative to return the "drug business license" to the provincial bureau.
August 7, the Yunnan Drug Administration issued a notice on Wenshan Huaxin San7 Co., Ltd. to voluntarily cancel the drug production license and GMP certificate.
on August 3rd, the Yunnan Drug Administration issued an announcement that Yunnan Hualian Yunbe Biopharmaceity Co., Ltd. had voluntarily cancelled its Drug Production License.
August 3, the Jiangxi Provincial Drug Administration issued an approval for agreeing to cancel the "Drug Production License" of Jiangxi Jishitang Pharmaceutical Co., Ltd.
Jiangxi Jishitang Pharmaceutical Co., Ltd. filed an application to cancel the "drug production license", in accordance with the relevant provisions, Jiangxi Pharmaceutical Regulatory Bureau agreed to cancel the company's "drug production license."
in the industry, in a large number of pharmaceutical companies announced the suspension of production, suspension of business activities, it is the pharmaceutical market reshuffle is accelerating.
On the one hand, with the strict supervision of the pharmaceutical industry, non-compliant enterprises will be straightened out, the industry will be developed in a standardized direction;